Right Knowledge. Right Place. Right Time. ECHO: A Revolutionary Model for Expanding Access to Specialized Care in Underserved Settings



NAFC Symposium 2017

THE UNIVERSITY OF CHICAGO MEDICINE

CommunityHealth, Community Health Care Clinic, Family Health Will-Grundy Medical Clinic, Tri-City Health Partnersh





h Partnership,





1

Objectives


- 1. Describe the ECHO model and its implementation in free and charitable clinics
- 2. Recognize the extensive resources the ECHO model offers to clinics in underserved settings
- 3. Discuss the impact of the model on education, provider knowledge, patient health outcomes and clinic-wide changes
- 4. Identify, locate and consider opportunities to participate in ECHO by collaborating with local ECHO hubs across the country

THE UNIVERSITY OF CHICAGO MEDICINE
















Americares Core U.S. Programs



Safety Net Support & Access to Medicine





Clinical Services









Emergency Programs

Community Health Programs

4

Americares, Loyola University Chicago, ECHO-Chicago, and IAFCC Free and Charitable Clinics (FCC) Initiative

- Collaboration among **four** strategic partners
- Implemented in **five** FCCs in Illinois
- Designed exclusively for FCC providers
- Goal: Assess feasibility and effectiveness of ECHO model in FCC setting
- Funding provided by the GE Foundation











FAMILY HEALTH Partnership Clinic







Characteristics of Participating Clinics

Clinic	Location	Annual Budget	# Patients	# Annual Visits		Volunteers	# HTN Patients	#/Type of ECHO Participants
Site E	Suburban	\$571,000	~1,000	~6000	5 RNs (3)	33 MDs 1 DO 7 NPs 42 RNs	198	1 NP (paid) 1 RN (paid)
Site D	Suburban	\$380,000	510	1,825	1 NP 1 RN	22 MDs 1 DO 24 RNs	67	1 NP (Clinic Dir) 1 MD (vol Med Dir)
Site C	Suburban	\$1.2 million	2,054	7,500	2 NPs (1.5) 4 RNs (2.5)		259	1 NP (paid) 2 RNs (paid) Note: 1 RN participated informally
Site B	Urban	\$580,000	1,500	10,000	2 (1.6)	130 MDs 5 DOs 5 NPs 6 RNs	288	1 NP (paid) 1 NP (paid)
Site A	Urban	\$3.0 million	10,500	23,000	1 NP 2 RNs	252 MDs 23 DOs 7 NPs 5 PAs 5 RNs	2,046	1 NP (Dir of Nursing) 1 RN 1 MD (vol Med Dir)







ECHO-Chicago Mission

The mission of ECHO-Chicago is to establish a robust community-based knowledge network that reduces the serious health disparities affecting children and adults in underserved communities.








ECHO: How it Works

The Extension for Community Health Outcomes (ECHO) uses *case-based, iterative,* telehealth delivered via high-grade videoconference technology to bring advanced training and support to community-based primary care providers



Agmericares



(ECHC




 Increase Access Improve Quality · Reduce Cost

Image courtesy of ECHO Institute



Best Practices + Knowledge Transfer + Technology = Force Multiplier





CHICAGO MEDICINE & BIOLOGICAL SCIENCES











ECHO-Chicago Disease Areas

Oct 2010 Dec 2011 Jan 2012 Mar 20 Apr 2014 Feb 2015 Feb 2016 Jun 2016 Sep 2016 Jan 2017 Feb 20

Resistant hypertension Pediatric ADHD

Risk based approach to women's health

Pediatric obesity & comorbidities

Hepatitis C

Child & youth epilepsy (not active)

Geriatrics

Behavioral health integration (system change)

Complex pediatric asthma

Hepatitis C case management

Behavioral health (clinic management)





ECHO Hubs and Superhubs: United States










Focus: Resistant Hypertension

- Disease area selected through collaborative discussion with FCC partners
- Leverage existing ECHO-Chicago infrastructure, experience and disease specific resources
- Mixed method approach
 - Quantitative analysis of patient and provider outcomes
 - **BP** control
 - Medication management
 - Qualitative/descriptive analysis of provider practices and clinic processes

THE UNIVERSITY OF CHICAGO MEDICINE

((ECHO







67 million adults with hypertension (30.4%)

CDC. MMWR 2012;61(35):203-9.



FCCs and ECHO

Several key factors impact how ECHO works in the FCC setting

- No federal funding for medications, supplies, lab tests
- Volunteer providers with variable experience delivering primary care to the • FCC patient population

This creates both challenges and opportunities



Photo credit: IAFCC

- Challenges
 - Identify the right clinic and provider partners
 - Support continuity of care consistent with FCC model
 - Disseminate knowledge among FCC staff/volunteers
- **Opportunities**

THE UNIVERSITY OF CHICAGO MEDICINE

- Engage clinic leadership
- Engage pharmacy/pharmacist
- Expand models for disseminating knowledge

((ECHC







ECHO-Chicago FCC Project

- Aim 1: Determine the **feasibility** of implementing the ECHO-Chicago intervention in free and charitable clinics
- Aim 2: Compare the **effectiveness** of the ECHO-Chicago intervention with conventional care in free and charitable clinics







Preliminary Findings



ECHO-Chicago FCC Project

- Aim 1: Determine the **feasibility** of implementing the ECHO-Chicago intervention in free and charitable clinics
- Aim 2: Compare the **effectiveness** of the ECHO-Chicago intervention with conventional care in free and charitable clinics









Study period 10/1/2015 and 5/10/2017 (586 day/ 1.6 year period) Total visits occurring in this time period: 4,849

Pre intervention	Post intervention
period	period
10/1/2015 -	2/22/2016 –
2/21/2016	5/10/2017
143 days	443 days
1,225 visits	3,623 visits
25% of total visits	75% of total visits







<u>n</u>

ts

Is ECHO *Feasible* in FCCs?








ECHO-Chicago HTN FCC Participants

■ All ECHO (2016-17) **FCC**




IAFCC



ECHO-Chicago HTN FCC Rates of Participation

	Total # of participants	Mean Attendance (# of sessions)
All ECHO HTN Participants (2016-17)	276	9
FCC ECHO HTN Participants	12	11



THE UNIVERSITY OF

CHICAGO MEDICINE

ECH

CHICAGO







20

Is ECHO *Effective* in FCCs?

- **Provider Level:**
 - Self Efficacy
 - Knowledge
 - Number of blood pressure readings taken
 - Adherence to guideline-concordant care
- Patient Level:
 - Reduction in systolic blood pressure
 - Improvement in blood pressure control
- Clinic Level:
 - Changes in policies and procedures affecting management of hypertensive patients

THE UNIVERSITY OF CHICAGO MEDICINE

((ЕСНО

Dissemination of knowledge







PROVIDER LEVEL










22


Self-Efficacy

		7.0		
7 r	point rating scale	6.0		
		5.0		
	Ability to identify patients with resistant hypertension\	4.0		
2.	Ability to assess the importance of kidney disease in	3.0 2.0		
	patients with hypertension	2.0		
3.	Ability to measure blood pressure accurately	0.0		
4.	Ability to manage side effects of hypertension		1	2
	medications			
5.	Ability to work collaboratively with patients to			
	effectively manage resistant hypertension			
6.	Ability to assess and manage comorbidities in patients	7.0		
	with resistant hypertension	6.0		
7	Overall ability to treat patients with resistant	5.0 -		
		4.0 -		
_	hypertension	3.0 -		
8.	Ability to select the most appropriate medication(s) for	2.0 -		
	patients with resistant hypertension	1.0 - 0.0 -		
9.	Ability to educate clinic staff about patients with	0.0	4	2
J.			T	2
	resistant hypertension			











Improving Provider Self-Efficacy

ECHO-trained providers emerged as HTN experts at 80% of participating clinics

"Our provider has become the expert and a champion for the program in our medical advisory committee and at our board meetings."





"My "new" NP grew so quickly because of the ECHO program. Her learning curve was greatly accelerated. Also, for myself and pharm tech we are much more knowledgeable in the full range of HTN meds and dosing and what are reasonable doses."







PATIENT LEVEL










25

Number of HTN Patients by Clinic








Patient Characteristics by Clinic

Characteristic	Overall	Clinic A	Clinic B	Clinic C
Age (mean)	55	56	53	54
% Female	55	63	48	58
Race/Eth				
% White	35	29	36	37
% Hispanic	56	67	40	54
% Black	4	7	16	0
% Other	5	2	8	9
% Non-English	64	86	37	51

Note: Differences across clinics are statistically significant at p<.0001









Patient Characteristics by Clinic

# of comorbidities	Overall %	Clinic A %	Clinic B %	Clinic C %	Clinic D %	Clinic E %
0	49	35	53	63	57	45
1	40	52	34	32	33	35
2	9	11	9	4	7	14
3	2	1	6	1	2	6

Notes: Maximum # of comorbidities = 19 Differences across clinics are statistically significant at p<.0001







Top Comorbidities by Clinic

Comorbidities	Overall %	Clinic A %	Clinic B %	Clinic C %	Clinic D %	Clinic E %
Diabetes	34	45	19	27	27	50
Diabetes w/ complications	8	10	8	5	11	6
Renal disease	5	7	0	4	9	5


Notes: Maximum # of comorbidities = 19 Differences across clinics are statistically significant at p<.0001








Changes in Systolic Blood Pressure by Clinic







Adjusted Differences in Systolic Blood Pressure

Variable	Coef	SE	K
Change in systolic blood	-3.99	2.17	•
pressure			

Note: Adjusted differences are derived from a regression-based difference-in-difference model that includes clinic sites, age, race, language spoken, and number of comorbidities. Standard errors are robust.






<mark>p-value</mark> .033



% of Patients with Controlled Blood Pressure




americares





% of Patients with Controlled Blood Pressure by Provider Type



	100%	% change
	90%	
	80%	
	70%	
	60%	
	50%	
	40%	
	30%	
	20%	
-0-	10%	
	0%	

CLINIC LEVEL









Changing Clinic Processes

Clinic	Implemented Patient Registry (100%)	Changed How BP was Taken (60%)	Identified new sources HTN Meds (40%)	Increased Frequency of Visits (80%)	lm I E R
SITE A	X			X	
SITE B	X	X	X	X	
SITE C	X	X		X	
SITE D	X				
SITE E	X	X	X	X	










CHICAGO

Disseminating Knowledge



CHICAGO







Conclusion

- Pilot points to the potential for ECHO to expand capacity at clinics delivering care to the most vulnerable patient population in the U.S.
 - Improved provider self-efficacy
 - Identified areas for improved clinic processes
 - Implemented ECHO in FCCs with minimal modifications
 - Important to be mindful of distinctive characteristics of FCCs
 - Engage clinic leadership
 - Availability of medications
 - Support for dissemination of ECHO knowledge

THE UNIVERSITY OF CHICAGO MEDICINE (((ECHO)

- Clinically meaningful improvements in systolic blood pressure among ECHO-trained providers
- Improvements in levels of blood pressure control clinic-wide







38

Participating Clinics



Community Health Care Clinic









Clinic Demographics

- Location: Normal, IL
- Size: 1,300 unduplicated patients; 10,000 square feet of space
- Patients:
 - Unique characteristics: Just moved in to a new building!
 - Hypertension: High prevalence of HTN

Age Range	Male/Female	Race	Geographic Area
19-64	45%/55%	White – 18%	McLean County
		Black – 9%	
		Hispanic – 68%	
		Other – 5%	







- FH is a long standing patient (2008) of the clinic (52 y.o Hispanic female). Many years of poorly controlled HTN, with minimal response to medication adjustments. Patient is compliant with meds. No other comorbidities.
- Ace + diuretic (lisinopril/HCTZ) for several years with GRADUALLY increased dosages. Minimal success with dosage increases.
 - Presented with decreased KCL on labs in December, 2015, added potassium 20 QD at that time. (Lisinopril 40, HCTZ 25) Added amlodipine 2.5 in January, 2016
 - KCL continued to decrease, HCTZ stopped in March, 2016. No change in BP with the ____ addition of 2.5 of amlodipine. BP recheck on 2/11/16 was 166/104, amlodipine increased to 10mg daily.
 - Appt. 2/18/16. Hypokalemia resolved with stopping HCTZ, but BP was 152/92 on Lisin ____ 40 and amlodipine 10. Added Spironolactone 12.5 QD.
 - Appt. 3/23/16, with BP of 150/98. Drilled MUCH farther down on salt intake, which _____ showed she is/was salt abuser. Spironolactone increased to 25 qd.
 - Appt. 4/21/16, with BP of 134/94. Patient stated has improved salt intake, continues med ____ compliance. BP readings remain consistent at the time of this writing.







Challenges and Results

- Much improvement in BP readings, the most progress that has been made with this _ patient since she started with the clinic.
- Faster increases in dosages, as well as salt education.
- The most major change with this patient was the salt investigation. Due to the ECHO project, there was no need to refer her out for specialist consultation on her NP.







Impact of ECHO on Clinic

- Improvements/changes in medication formulary based on recommendations from Dr. Bakris (chlorthalidone, endapimide)
- Much more emphasis on salt intake, more aggressive dosing, better understanding of significance of renal function changes
- The opportunity to provide better patient outcomes!
- Better overall understanding of the whole picture to addressing HTN (diet, meds, compliance)
- Information was shared with key staff during our Wednesday afternoon staffing sessions with our NPs, medical director, dispensary coordinator, ED, and Operations Manager Providers immediately started increased education on salt intake and counseling on how to
- make changes in diet
- Analyzed our internal dispensary inventory and made the necessary changes to supply based on the recommendations of Dr. Bakris

THE UNIVERSITY OF CHICAGO MEDICINE

((ЕСНО







CommunityHealth

- About 9,000 patients
- About 16,000 provider visits per year
- Over 1000 volunteers, including over 300 providers
- Services provided include:

Primary Care Specialty Care Lab Work **Medications Dental Care** Health Education

Social Services/Mental Health













45

- 74yo Hispanic woman with diabetes, HTN, hyperlipidemia, hypothyroidism, anemia, and a history of hospitalization for hyponatremia.
- Had been on lisinopril 40mg QD and ToproIXL 100mg QD. Lisinopril was stopped in hospital due to hyponatremia in Dec 2015.
- At 12/16/15 visit BP was 132/64 on ToproIXL only.
- At 3/16/16 visit BP was 170/70 on ToproIXL only. ToproI was d/c'd and amlodipine 5mg QD started. Low sodium diet was discussed.
- At 3/26/16 BP check, BP is 174/90 and amlodipine is increased to 10mg.
- 3/28/16 case presented to ECHO: addition of very low dose furosemide recommended if BP still not controlled.
- At 4/27/16 visit, BP is 150/70 and furosemide 10mg QD is added.
- 5/2/16 case presentation to ECHO: d/c of furosemide, reduction of amlodipine, and addition of carvedilol recommended.
- 5/23/16 visit, BP is 136/60 and sodium level is stable, so no changes made.
- 7/20/16 visit, BP is 160/70 and carvedilol 3.125mg BID is added. (Perhaps should have stopped furosemide and started higher dose of carvedilol.)

THE UNIVERSITY OF CHICAGO MEDICINE

• 10/12/16 visit, BP is 140/60 and sodium and potassium are stable.







(ECHO

Challenges and Results

- BP improvement from 170/70 to 140/60 with stable electrolytes in an elderly woman. —
- Improvements based on optimized medications and low sodium counseling ____
- Improved knowledge of role of salt and role for each medication class contributed to ____ **SUCCESS**
- Consider d/c of furosemide and increase of carvedilol next visit?
- If possible, more "real time" consultations would be helpful for patient cases as often the ____ patient visits and patient case presentations don't align

THE UNIVERSITY OF CHICAGO MEDICINE

((ECHO







Impact of ECHO on Clinic

- Increased focus on blood pressure control clinic-wide (leader board and huddles)
- Development of updated hypertension treatment guidelines specific to clinic formulary with leadership from multiple key providers
- Development of HTN Care Group
- Identification of a low literacy sodium handout
- Improvements in BP control from Q1 to Q3 clinic-wide:
 - BP <140/90 in DM: 66% in Q1 to 72% in Q3</p>
 - BP < 140/90 in 18-59yo pts w HTN: 43% in Q1 to 49% in Q3
 - BP < 150/90 in pts 60+ w/o DM or CKD: 59% in Q1 to 73% in Q3

THE UNIVERSITY OF CHICAGO MEDICINE

((ЕСНО






d huddles) clinic formulary













Initial Drugs of Choice for Hypertension Angiotensin receptor blocker (ARB)

Start one drug, titrate to maximum dose, and then add a second drug.

Start one drug, then add a second drug before achieving max dose of

Begin 2 drugs at same time, as separate pills or combination pill. Initial combination therapy is recommended if BP is greater than 20/10mm Hg above goal

Control blood glucose and lipids

✓ Eat healthy (i.e., DASH diet) ✓ Moderate alcohol consumption ✓ Reduce sodium intake to no more than 2,400 mg/day ✓ Moderate-to-vigorous activity 3-4 days a week averaging 40

	C	ompelling Indications		Hypertens	
Indication		Treatment Choice		at Comm	
Heart Failure		ACEI/ARB + BB + diuretic + spironolactone			
Post – MI/Clinical	CAD	ACEI/ARB AND BB			
CAD		ACEI, BB, diuretic, CCB	в	eta-1 Selective Beta-blo	
Diabetes		ACEI/ARB, CCB, diuretic		vith COPD, asthma, diabe	
CKD		ACEI/ARB		isease: metoprolol succinate 50	
Recurrent stroke	prevention	ACEI, diuretic			
Drug Class		Agents of Choice			
Thiazide Diuretics	Chlorthalidon	thalidone 12.5-25 mg daily, HCTZ 12.5-50 mg daily		Monitor for hypokal Most SE are metabo Most effective when	
Other diuretics	<i>K+ sparing</i> – spironolactone 25-50mg daily, triamterene/HCTZ 37.5/25mg daily furosemide 20-80mg twice daily			Stronger clinical evide Spironolactone - gyneo Loop diuretics may be	
ACEI/ARB	ACEI: Lisinopril 10-40mg daily ARB: Losartan 50-100mg daily			SE: Cough (ACEI only), hyperkalemia Losartan lowers uric a	
Beta-Blockers	carvedilol 6.25-25mg twice daily, propranolol 40-120mg twice daily. for Beta-1-Selective – outside script is needed (i.e. metoprolol succinate 50- 100mg daily)		50-	Not first line agents – Cause fatigue and dec Adversely affect gluco	
Calcium channel blockers	Dihydropyridines: amlodipine 5-10mg, nifedipine ER 30-90mg Non-dihydropyridines: verapamil ER 240-480mg daily			Cause edema; dihydro w/ B-blocker Non-dihydropyridines	
Centrally-acting Agents	clonidine 0.1-0.2mg twice daily			Clonidine weekly patch script for resistant hyp	
Vasodilators	terazosin 1-5mg daily			Alpha-blockers may ca caution in CHF, ECHO	







sion Treatment munityHealth

lockers – possibly safer in patients betes, and peripheral vascular

50-100mg daily (outside script)

Comments

- emia
- ic in nature
- combined w/ ACEI
- ence w/chlorthalidone
- ecomastia and hyperkalemia
- e needed when GFR <40mL/min
-), angioedema (more with ACEI),

acid levels

- reserve for post-MI/CHF creased heart rate ose; mask hypoglycemic awareness
- opyridines may be safely combined
- s reduce heart rate and proteinuria
- ch formulation available via outside pertension

ause orthostatic hypotension,) recommended



FAMILY HEALTH Partnership Clinic









- Hispanic female, 56, first visit July 2014 to establish care. Hx breast CA on tamoxifen.
- Lives in Harvard, 25 miles from clinic.
- Took 1 ¹/₂ year and 9 provider visits to control her BP. Saw 4 providers. Got BP under control after Sara Brubacher applied knowledge from ECHO to change RX.









Date	CC/Exam	BP	BP Rx	RX change	Provider
7/15/14	56 Hispanic F establish care. CC leg pain wakes her up at night. Hx breast CA 2012 Only Rx is tamoxifen	165/90; 136/82 P: 77/Wt 224#/BMI 38	NONE	levothyroxine 25mcg, lovastatin 20 mg after labs drawn today	JM (MD)
3/30/15	Always thirsty, leg pain continues at night; mild bilat. ankle edema on exam. More labs today.	159/86	NONE	Losartan 50mg QD	MS (NP)
8/27/15	Discuss FPG 117; leg cramp/burning	140/100	losartan 50 mg QD	gabapentin 300 TID	KW (NP)
11/2/15	Legs still hurt at night, gabapentin		locartan 50 mg OD		KW (ND)
11/3/15	not helping ECHO program January - March	176/92; 148/84	losartan 50 mg QD	NONE	(NP)

americares





ILLINOIS ASSOCIATION OF FREE & CHARITABLE CLINICS () IAFCC

			HCTZ 25mg QD; Losartan 100mg QD; spironolactone 25 mg	
		HCTZ 12.5 QD		SB (NP)
/U; bought cuff for home, BPs	144/86		U	SB (NP)
/U; home SBP 130-150, 30-100	134/84	losartan 100 mg QD; HCTZ 25 mg QD; spironolactone 25mg QD	Continue HCTZ 25 QD and spironolactone	SB (NP)
etes F/U		amlodipine 10, benazepril 40, HCTZ 25, spironolactone 25	metformin 500 mg BID	
	00 at home U; home SBP 130-150, D-100	D0 at home 144/86 U; home SBP 130-150, 134/84 D-100 134/84 tes F/U 125/75	U; bought cuff for home, BPs 20 at home 144/86 HCTZ 25 mg QD; spironolactone 25mg QD losartan 100 mg QD; HCTZ 25 mg QD; Spironolactone 25mg QD 134/84 amlodipine 10, benazepril 40, HCTZ 25, spironolactone 25	U; bought cuff for home, BPs 20 at home 144/86 HCTZ 25 mg QD; spironolactone 25mg QD Stop losartan. Start amlodipine 10/benazepril 40. Continue HCTZ 25 QD and spironolactone 25mg QD and spironolactone 25mg QD amlodipine 10, benazepril 40, HCTZ 25, spironolactone 25 mg QD amlodipine 10, benazepril 40, HCTZ 25, spironolactone 25 mg QD







What did we learn?

Took nearly 2 years to control this patient's blood pressure

- 50 mile round trip for each appointment
- 12+ appointments over 2-year time frame
- "Wait and see" attitude by some providers
- Incremental medication changes too conservative to achieve results
- Providers' reliance on their own formulary often doesn't include calcium channel blockers or the use of 2 diuretics

THE UNIVERSITY OF CHICAGO MEDICINE

((ECHO





results de calcium



Impact of ECHO on Clinic

- Compiled clinical pearls handout based on ECHO learning and distributed to all providers
- RNs educated on correct BP measurement technique
- 16-week CareMessage texting program geared toward hypertensive patients
- Goals: chronic disease registry; lunch and learn case presentations







Questions and Discussion











57

Acknowledgements

- Christina Newport, Americares
- Julie Darnell, Loyola University
- Heather Pauls, University of Illinois at Chicago
- Leslie Ramyk, IAFCC
- Melissa Maguire, IAFCC
- Daniel Johnson, ECHO-Chicago
- Tamara Hamlish, ECHO-Chicago
- Stephanie Zass, ECHO-Chicago
- Leadership, staff, and volunteers at participating clinics
- **GE** Foundation









58